Clinical trial · Observational
Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study
Comparative Effectiveness of Breast Cancer Screening and Diagnostic Evaluation by Extent of Breast Density
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This Breast Cancer Surveillance Consortium (BCSC) ADVANCE study is a large, observational pragmatic comparative effectiveness research study using high-quality, prospectively collected data from BCSC registries to generate evidence on how breast density should be integrated into decision making around breast cancer screening and preoperative diagnostic work-up. We will augment existing BCSC registry infrastructure with additional prospective data collection and collection of patient reported outcomes (PROs), CISNET modeling of long-term screening outcomes, and qualitative data from focus groups with women represented in two aims.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic mammography | Other | — | UNRESOLVED |
| Pre-operative breast magnetic resonance imaging | Other | — | UNRESOLVED |
| Screening breast magnetic resonance imaging | Other | — | UNRESOLVED |
| Screening digital breast tomosynthesis | Other | — | UNRESOLVED |
| Screening digital mammography | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Screening group
- description
- Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
- interventionNames
- Other: Screening digital mammography
- Other: Screening digital breast tomosynthesis
- Other: Screening breast magnetic resonance imaging
- label
- Women with breast cancer
- description
- Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
- interventionNames
- Other: Diagnostic mammography
- Other: Pre-operative breast magnetic resonance imaging
Primary outcomes (10)
- measure
- Screening Benefits: Rate of early stage invasive cancer detection (Aim 1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Aim 1 Clinical Outcomes Inclusion criteria: * Women aged 40-79 undergoing screening mammography from 2010-2017 for comparisons with tomosynthesis and 2005-2017 for comparison with breast MRI at a facility that participates in one of six BCSC breast imaging registries * Digital mammography exams performed for screening and performed with or without supplemental screening with digital breast tomosynthesis from 2010-2017 or breast MRI from 2005-2017, at a facility that participates in one of seven BCSC breast imaging registries, and in women who meet inclusion criteria. Exclusion criteria: * Exams performed on women with a history of breast cancer, mastectomy, or breast augmentation. * Unilateral mammograms and mammograms performed within 9 months of a prior mammogram to avoid classifying diagnostic exams as screening * Exams without complete cancer capture during the follow-up period Aim 1 Patient Reported Outcomes Inclusion criteria: * Women aged 40-74 years undergoing screening mammography, with or without supplemental screening with digital breast tomosynthesis or breast MRI, at selected BCSC facilities * Women within 12 months of a digital screening mammogram with known breast density and no known breast cancer diagnosis * For MRI subgroup, we will include women with a screening MRI within the prior 24 months * Within strata defined by BCSC registry, breast density subgroup (dense vs. not dense), and race/ethnicity, women with supplemental screening with digital breast tomosynthesis or breast MRI will be matched to women without supplemental screening Aim 1 Focus Groups Inclusion criteria: * Women age 40-74 years undergoing screening mammography, with or without supplemental screening (defined as digital breast tomosynthesis or breast MRI) * Women within 12 months post-most recent screening examination with known dense breasts from most recent screening mammogram and no known breast cancer diagnosis * Women who are able to speak English and can travel to a nearby location for a discussion Subaim 1 Inclusion criteria: * Radiologists interpreting digital mammography and/or tomosynthesis for at least one year from 2010-2017 at a facility that participates in the BCSC * Digital mammography exams and digital breast tomosynthesis performed for screening and evaluated by a radiologist meeting inclusion criteria from 2010-2017 Exclusion criteria: * Exams performed on women with a history of breast cancer, mastectomy, or breast augmentation * Unilateral mammograms and mammograms performed within 9 months of a prior mammogram to avoid classifying diagnostic exams as screening * Exams without complete cancer capture during one year following the screening mammogram Aim 2 Clinical Outcomes Inclusion criteria: * Women at least 18 years of age with a first breast cancer diagnosis (DCIS or invasive) from 2005-2017 for whom there was a mammogram performed within the year prior to breast cancer diagnosis at one of the participating BCSC registry facilities * Women for whom we have pathologically-confirmed breast cancer (DCIS or invasive) with a pathology or biopsy record related to the incident cancer diagnosis in the BCSC data * MRI and mammography examinations performed for pre-operative work-up from 2005-2017 at one of the participating BCSC registry facilities in women meeting eligibility criteria Aim 2 Patient Reported Outcomes Inclusion criteria: * Women at least 18 years of age with a first pathology-confirmed breast cancer diagnosis (DCIS or stage I-III invasive) within 6-18 months * Known breast density at the time of breast cancer diagnosis Aim 2 Focus Groups Inclusion criteria: * Women age ≥18 with a first breast cancer diagnosis (DCIS or stage I-III invasive cancer) within 1-5 years and after completion of active breast cancer treatment who have undergone mammography or MRI pre-operatively. * Women who are able to speak English and can travel to a nearby location for a discussion COVID-19 Enhancement Focus Groups Inclusion criteria: * Women age 18-74 who were due for breast imaging services during the COVID pandemic and have either canceled their appointment, delayed their appointment, or kept their appointment * Women who are able to speak English and can attend calls virtually through Zoom or over the phone * In addition, for focus groups with women who have prior breast cancer: 1. First breast cancer diagnosis (DCIS or stage I-III invasive cancer) within 1-3 years prior to March, 2020. 2. Completed active cancer treatment (ongoing endocrine and Herceptin therapy acceptable) 3. No evidence of a second breast cancer event in cancer registry or pathology data before recruitment.
References
Publications (3)
- DERIVEDSmith RE, Sprague BL, Henderson LM, Kerlikowske K, Miglioretti DL, Wernli KJ, Onega T, diFlorio-Alexander RM, Tosteson ANA. Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer. Breast Cancer Res. 2024 Apr 29;26(1):73. doi: 10.1186/s13058-024-01820-x. PMID 38685119
- DERIVEDTosteson ANA, Schifferdecker KE, Smith RE, Wernli KJ, Zhao W, Kaplan CP, Buist DSM, Henderson LM, Sprague BL, Onega T, Budesky J, Jackson-Nefertiti G, Johnson D, Miglioretti DL, Kerlikowske K. Women's Breast Cancer Screening Confidence by Screening Modality and Breast Density: A Breast Cancer Surveillance Consortium Survey Study. J Womens Health (Larchmt). 2022 Nov;31(11):1547-1556. doi: 10.1089/jwh.2021.0649. PMID 36356184
- DERIVEDOnega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, Wernli KJ, diFlorio R, Weaver DL, Buist DSM. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast Cancer Res Treat. 2022 Jan;191(1):177-190. doi: 10.1007/s10549-021-06418-x. Epub 2021 Oct 22. PMID 34686934